Shruthi Venkatesh

Shruthi Venkatesh

Auto-generated profile, based on publicly available information

Shruthi Venkatesh

Department of Neurology, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SLSeth N. Levin
Seth N. Levin
SVShruthi Venkatesh
Shruthi Venkatesh
KNKatie E. Nelson
Katie E. Nelson
YLYi Li
Yi Li
IAInes Aguerre
Ines Aguerre
MCMultiple Sclerosis Resilience to COVID‐19 (MSReCOV) Collaborative
Multiple Sclerosis Resilience to COVID‐19 (MSReCOV) Collaborative
Objective: To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS).Methods: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID‐19 in persons with NID (PwNID) and change in their neurological care.Results: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID‐19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID‐19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID‐19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID‐19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID‐19 (ORadj = 1.45, 1.17–1.84).Interpretations: Our study of real‐time, patient‐reported experience during the COVID‐19 pandemic complements physician‐reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID‐19 similar to the reference population.

24 August 2022 in JMIR Mental Health
Verified
Journal Article
Open access
PCPrerna Chikersal
Prerna Chikersal
SVShruthi Venkatesh
Shruthi Venkatesh
KMKarman Masown
Karman Masown
EWElizabeth Walker
Elizabeth Walker
DQDanyal Quraishi
Danyal Quraishi
ZXZongqi Xia
Zongqi Xia
Background: The COVID-19 pandemic has broad negative impact on the physical and mental health of people with chronic neurological disorders such as multiple sclerosis (MS). Objective: We presented a machine learning approach leveraging passive sensor data from smartphones and fitness trackers of people with MS to predict their health outcomes in a natural experiment during a state-mandated stay-at-home period due to a global pandemic. Methods: First, we extracted features that capture behavior changes due to the stay-at-home order. Then, we adapted and applied an existing algorithm to these behavior-change features to predict the presence of depression, high global MS symptom burden, severe fatigue, and poor sleep quality during the stay-at-home period. Results: Using data collected between November 2019 and May 2020, the algorithm detected depression with an accuracy of 82.5% (65% improvement over baseline; F1-score: 0.84), high global MS symptom burden with an accuracy of 90% (39% improvement over baseline; F1-score: 0.93), severe fatigue with an accuracy of 75.5% (22% improvement over baseline; F1-score: 0.80), and poor sleep quality with an accuracy of 84% (28% improvement over baseline; F1-score: 0.84). Conclusions: Our approach could help clinicians better triage patients with MS and potentially other chronic neurological disorders for interventions and aid patient self-monitoring in their own environment, particularly during extraordinarily stressful circumstances such as pandemics, which would cause drastic behavior changes.

3 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ZXZongqi Xia
Zongqi Xia
PCPrerna Chikersal
Prerna Chikersal
SVShruthi Venkatesh
Shruthi Venkatesh
EWElizabeth Walker
Elizabeth Walker
ADAnind Dey
Anind Dey
MGMayank Goel
Mayank Goel
Background: Longitudinal tracking of multiple sclerosis (MS) symptoms in an individual’s environment may improve self-monitoring and clinical management for people with MS. Conventional symptom tracking methods rely on self-reports and clinical visits, which can be infrequent, subjective, and burdensome. Digital phenotyping using passively collected sensor data from smartphones and fitness trackers offers a promising alternative for continuous, real-time symptom monitoring with minimal patient burden. Objective: We aimed to develop and evaluate a machine learning (ML)–based digital phenotyping approach to monitor the severity of clinically-relevant MS symptoms. We used passive sensing data to predict short-term fluctuations in patient-reported symptoms, including depressive symptoms, global MS symptom burden, severe fatigue, and poor sleep quality. Further, we examined the impact of incorporating behavioral context features and ecological momentary assessments on prediction performance. Methods: We conducted a 12- to 24-week longitudinal study involving 104 people with MS, collecting passive sensor and behavioral health data. Smartphone sensors recorded call activity, location, and screen use, while fitness trackers captured heart rate, sleep patterns, and step count. We extracted patient-level behavioral features and categorized them into 2 feature sets: one from the prediction period (called action) and one from the preceding period (called context). Using an ML pipeline based on support vector machines and AdaBoost, we evaluated the predictive performance of sensor-based models, both with and without ecological momentary assessment inputs. Results: Between November 16, 2019, and January 24, 2021, overall, 104 people with MS (women: n=88, 84.6%; non-Hispanic White: n=97, 93.3%; mean age 44, SD 11.8 years) from a clinic-based cohort completed 12 weeks of data collection, including a subset of 44 participants (women: n=39, 89%; non-Hispanic White: n=42, 95%; mean age 45.7, SD 11.2 years) who completed 24 weeks of data collection. In total, we collected approximately 12,500 days of passive sensor and behavioral health data from the participants. Among the best-performing models with the least sensor data requirement, the ML algorithm predicted depressive symptoms with an accuracy of 80.6% (F1-score=0.76), high global MS symptom burden with an accuracy of 77.3% (F1-score=0.78), severe fatigue with an accuracy of 73.8% (F1-score=0.74), and poor sleep quality with an accuracy of 72.0% (F1-score=0.70). Further, sensor data were largely sufficient for predicting symptom severity, while the prediction of depressive symptoms benefited from minimal active patient input in the form of responses to 2 brief questions on the day before the prediction point. Conclusions: Our digital phenotyping approach using passive sensors on smartphones and fitness trackers may help patients with real-world, continuous self-monitoring of common symptoms in their own environment and assist clinicians with better triage of patient needs for timely interventions in MS and potentially other chronic neurological disorders.

1 January 2021 in Journal of Central Nervous System Disease
Verified
Journal Article
Open access
PDF file
TMThomas Mathew
Thomas Mathew
KTKurian Thomas
Kurian Thomas
SJSaji K John
Saji K John
SVShruthi Venkatesh
Shruthi Venkatesh
RNRaghunandan Nadig
Raghunandan Nadig
GPGareth J Parry
Gareth J Parry
Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC). This retrospective, observational study, conducted at a tertiary care, neuroimmunology clinic, analyzed the data of patients with AChR antibody positive gMG, treated with rituximab between 1st January 2016 and 30th October 2018. Eleven patients with AChR antibody positive gMG received rituximab. Mean age of the cohort was 50.54 ± 18.71 years with 9 males. Seven out of 11 patients received rituximab in the early stage (<2 years from onset) and had good response to treatment. Four of the 5 patients with IMC improved with rituximab alone. In the 10 patients who regularly followed up, there was a significant difference between the QMG scores at baseline and at 1, 2, 6, 12, and 18 months (P < .0001). Rituximab appears to be a potentially effective early treatment option for AChR antibody positive generalized MG and impending myasthenic crisis.

6 February 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
CRClaire Riley
Claire Riley
SVShruthi Venkatesh
Shruthi Venkatesh
ADAmar Dhand
Amar Dhand
NDNandini Doshi
Nandini Doshi
KKKatelyn Kavak
Katelyn Kavak
ZXZongqi Xia
Zongqi Xia
Background: The coronavirus disease 2019 (COVID-19) pandemic has negatively affected the social fabric. Objective: We evaluated the associations between personal social networks and neurological function in people with multiple sclerosis (pwMS) and controls in the prepandemic and pandemic periods. Methods: During the early pandemic (March-December 2020), 8 cohorts of pwMS and controls completed a questionnaire quantifying the structure and composition of their personal social networks, including the health behaviors of network members. Participants from 3 of the 8 cohorts had additionally completed the questionnaire before the pandemic (2017-2019). We assessed neurological function using 3 interrelated patient-reported outcomes: Patient Determined Disease Steps (PDDS), Multiple Sclerosis Rating Scale-Revised (MSRS-R), and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function. We identified the network features associated with neurological function using paired 2-tailed t tests and covariate-adjusted regressions. Results: In the cross-sectional analysis of the pandemic data from 1130 pwMS and 1250 controls during the pandemic, having a higher percentage of network members with a perceived negative health influence was associated with worse disability in pwMS (MSRS-R: β=2.181, 95% CI 1.082-3.279; P<.001) and poor physical function in controls (PROMIS Physical Function: β=–5.707, 95% CI –7.405 to –4.010; P<.001). In the longitudinal analysis of 230 pwMS and 136 controls, the networks of all participants contracted, given an increase in constraint (pwMS-prepandemic: mean 52.24, SD 15.81; pwMS-pandemic: mean 56.77, SD 18.91; P=.006. Controls-prepandemic: mean 48.07, SD 13.36; controls-pandemic: mean 53.99, SD 16.31; P=.001) and a decrease in network size (pwMS-prepandemic: mean 8.02, SD 5.70; pwMS-pandemic: mean 6.63, SD 4.16; P=.003. Controls-prepandemic: mean 8.18, SD 4.05; controls-pandemic: mean 6.44, SD 3.92; P<.001), effective size (pwMS-prepandemic: mean 3.30, SD 1.59; pwMS-pandemic: mean 2.90, SD 1.50; P=.007. Controls-prepandemic: mean 3.85, SD 1.56; controls-pandemic: mean 3.40, SD 1.55; P=.01), and maximum degree (pwMS-prepandemic: mean 4.78, SD 1.86; pwMS-pandemic: mean 4.32, SD 1.92; P=.01. Controls-prepandemic: mean 5.38, SD 1.94; controls-pandemic: mean 4.55, SD 2.06; P<.001). These network changes were not associated with worsening function. The percentage of kin in the networks of pwMS increased (mean 46.06%, SD 29.34% to mean 54.36%, SD 30.16%; P=.003) during the pandemic, a change that was not seen in controls. Conclusions: Our findings suggest that high perceived negative health influence in the network was associated with worse function in all participants during the pandemic. The networks of all participants became tighter knit, and the percentage of kin in the networks of pwMS increased during the pandemic. Despite these perturbations in social connections, network changes from the prepandemic to the pandemic period were not associated with worsening function in all participants, suggesting possible resilience.

12 March 2026 in Communications Medicine
Verified
Journal Article
Open access
SVShruthi Venkatesh
Shruthi Venkatesh
LWLinshanshan Wang
Linshanshan Wang
MMMichele Morris
Michele Morris
MMMohammed Moro
Mohammed Moro
RSRatnam Srivastava
Ratnam Srivastava
ZXZongqi Xia
Zongqi Xia
Alzheimer's disease (AD) carries a high societal burden inequitably distributed across demographic groups. Using real-world electronic health record (EHR) data with accurate population identification, we examine demographic differences and potentially modifiable drivers of AD decline. Leveraging EHR data (1994-2022) from two large independent healthcare systems, we applied an unsupervised phenotyping algorithm to predict AD diagnosis and validated using gold-standard chart-reviewed and registry-derived diagnosis labels. Among patients with ≥24 months of EHR data not living in nursing homes pre-AD diagnosis, we estimated the time-to-decline (nursing home admission, death) in healthcare system-specific covariate-adjusted competing risk survival analyses stratified by demographic groups. We then performed covariate-adjusted fixed-effects meta-analyses using inverse variance weighting. The algorithm demonstrates robust performance in identifying AD populations across healthcare systems and demographic groups (AUROC score range: 0.835-0.923). Of the 29,262 AD patients in both healthcare systems (61% women, 90% non-Hispanic White, 79.52 ± 9.39 years of age at AD diagnosis), 49% transition to nursing homes and 52% die during follow-up. In covariate-adjusted fixed-effects meta-analysis, women have higher nursing home admission risk (HR [95% CI] = 1.061 [1.024-1.100], p = 1.203×10-3) but lower death risk (HR [95% CI] = 0.856 [0.811-0.904], p = 2.434×10-8) than men. Non-Hispanic White individuals have similar nursing home risk (HR [95% CI] = 1.006 [0.952-1.063], p = 8.306×10-1) but higher death risk (HR [95% CI] = 1.376 [1.245-1.521], p = 4.084×10-10) than racial and ethnic minorities. Older age at AD diagnosis and greater comorbidity burden increase both nursing home admission and death risk. We provide real-world evidence of drivers of demographic differences in AD decline that could inform individual clinical management and public health policies.